Form 8-K - Current report:
SEC Accession No. 0001558370-24-015441
Filing Date
2024-11-13
Accepted
2024-11-13 08:08:42
Documents
15
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mgtx-20241113x8k.htm   iXBRL 8-K 38134
2 EX-99.1 mgtx-20241113xex99d1.htm EX-99.1 237343
3 GRAPHIC mgtx-20241113xex99d1001.jpg GRAPHIC 3029
  Complete submission text file 0001558370-24-015441.txt   421948

Data Files

Seq Description Document Type Size
4 EX-101.SCH mgtx-20241113.xsd EX-101.SCH 3123
5 EX-101.LAB mgtx-20241113_lab.xml EX-101.LAB 15930
6 EX-101.PRE mgtx-20241113_pre.xml EX-101.PRE 10055
17 EXTRACTED XBRL INSTANCE DOCUMENT mgtx-20241113x8k_htm.xml XML 4911
Mailing Address 450 EAST 29TH STREET 14TH FLOOR NEW YORK NY 10016
Business Address 450 EAST 29TH STREET 14TH FLOOR NEW YORK NY 10016 646-860-7985
MeiraGTx Holdings plc (Filer) CIK: 0001735438 (see all company filings)

EIN.: 981448305 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38520 | Film No.: 241451281
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)